Clinical Trials Logo

Ankylosing Spondylitis clinical trials

View clinical trials related to Ankylosing Spondylitis.

Filter by:

NCT ID: NCT05968469 Recruiting - Clinical trials for Ankylosing Spondylitis

The Effects of Aerobic Exercise in Patients With Ankylosing Spondylitis

Start date: July 30, 2023
Phase: N/A
Study type: Interventional

The aim of our study is to investigate the effects of aerobic exercise and stretching exercises applied in high-intensity interval training protocol on disease activity, quality of life, spinal mobility and calprotectin, visfatin, leptin, IL-33 serum levels in patients with Ankylosing Spondylitis.

NCT ID: NCT05962762 Not yet recruiting - Clinical trials for Ankylosing Spondylitis

Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Ankylosing Spondylitis

Start date: August 30, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with Ankylosing Spondylitis, and to further explore the efficacy, pharmacodynamic profile and appropriate dose of administration to provide a basis for the use of safer and more effective treatments for patients with Ankylosing Spondylitis in the future. Participants are required to sign an informed consent form and, after undergoing a series of tests and meeting the protocol's entry and exclusion criteria, are assigned to a dose group for intravenous infusion of human umbilical cord mesenchymal stem cells.

NCT ID: NCT05913817 Recruiting - Clinical trials for Rheumatoid Arthritis

The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.

EASE PAIN
Start date: January 9, 2023
Phase:
Study type: Observational

The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market. The phase IV study is an observational, pan-Canadian, multidisciplinary study aiming to enroll 600 patients across 50-70 sites across 3 different Therapeutic Areas (GI, Rheum, Derm).

NCT ID: NCT05883371 Recruiting - Psoriasis Clinical Trials

IMPACT - AndHealth Autoimmune Research Registry

Start date: June 8, 2023
Phase:
Study type: Observational [Patient Registry]

This is a patient research registry aimed at evaluating the effectiveness of a comprehensive, root-cause medical approach ("AndHealth program") for autoimmune disorders. This approach involves a combination of pharmacological and non-pharmacological therapies offered under the care of a licensed physician with the support of health coaches. While protocol guidance is provided, the therapeutic approach is personalized to the individual needs of patients. The autoimmune disorders of focus in this registry include rheumatoid arthritis, psoriatic arthritis, psoriasis and ankylosing spondylitis. A variety of validated labs, patient-reported outcomes, and medication usage will be assessed among participating patients over a period of up to five years to evaluate the long-term effectiveness of this approach.

NCT ID: NCT05866614 Recruiting - Clinical trials for Rheumatoid Arthritis

A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps

Start date: January 13, 2023
Phase:
Study type: Observational [Patient Registry]

This is an observational, prospective cohort study to evaluate the safety of Remsima® SC in the treatment of RA, AS, PsA and Ps.

NCT ID: NCT05862584 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Impact of Air Pollution on the Course of Inflammatory Rheumatism

Start date: May 26, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to see if there is a link between air pollution and inflammatory rheumatism (rheumatoid arthritis and ankylosing spondylitis) To do this, the investigators are going to follow a cohort of about 200-400 patients for 6 months by means of a self-questionnaire, which the investigators ask the patient to fill in once a week on a fixed day, and opposite the corresponding week to put the letter corresponding to the question concerning the activity of your disease: 3 possible answers: A: no flare-up, B: short flare-up of 1 to 3 days, C: persistent flare-up of more than 3 days Then the investigators will collect the questionnaire at the end of these 6 months and at each visit to the consultation or day hospital (on average every 4 to 6 weeks), and they will look to see if any relapses have occurred. At the same time the investigators will calculate the disease activity score (DAS or BASDAI) to have an objective score. Then in parallel they will look at the level of exposure to air pollution according to the place of residence and work of each patient. The hypothesis is that air pollution has an influence on the activity of inflammatory rheumatism.

NCT ID: NCT05861128 Recruiting - Clinical trials for Ankylosing Spondylitis

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

Start date: November 10, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.

NCT ID: NCT05861102 Recruiting - Clinical trials for Ankylosing Spondylitis

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Start date: July 20, 2023
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Jaktinib in subjects with active Ankylosing Spondylitis(AS).

NCT ID: NCT05839925 Completed - Clinical trials for Ankylosing Spondylitis

Prevalence of Temporomandibular Joint Dysfunction in Patients With Ankylosing Spondylitis

Start date: April 1, 2022
Phase:
Study type: Observational

This study included 113 patients diagnosed with ankylosing spondylitis and 110 healthy volunteers. Participants in both groups were evaluated using the 'Diagnostic Criteria for Temporomandibular Disorders (DC/TMD)' diagnostic criteria. In addition, the relationship between temporomandibular joint dysfunction and disease activity was investigated in patients with ankylosing spondylitis.

NCT ID: NCT05835518 Recruiting - Clinical trials for Rheumatoid Arthritis

An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With RA and AS

Start date: January 26, 2023
Phase:
Study type: Observational

This Study is to Assess the Efficacy and Safety of Adalloce in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis, An Observational, Prospective Study